Heart Test Laboratories announced the close of a non-dilutive financing, with $1.9 million in net proceeds. The unsecured loan note has an 18-month maturity date and follows the recent 12-month extension of a $500,000 loan note to September 2025. Andrew Simpson, CEO of HeartSciences, said, “We have extended our capital runway by $2.4 million since late August ahead of our upcoming FDA submissions. This has been achieved with non-dilutive capital and provides significant opportunity for HeartSciences to hit a number of valuable commercial milestones.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSCS:
- HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
- Heart Test Laboratories closes non-dilutive financing
- HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
- HSCS Upcoming Earnings Report: What to Expect?
- HeartSciences raised $10.3M in proceeds from stock sales , FDA submission close